Whole-body 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Demonstrating Multiple Rare Extracranial Metastases in a Treated Case of Glioblastoma

Koramadai Karuppusamy Kamaleshwaran; Elumalai Ramkumar; Madhu Sairam Raghunathan

doi:10.4103/ijnm.ijnm_167_22

View/Download PDF

Buy Reprints

PDF

Translate this page into:

Interesting Image

38 (

); 294-296

doi:

10.4103/ijnm.ijnm_167_22

Whole-body ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Demonstrating Multiple Rare Extracranial Metastases in a Treated Case of Glioblastoma

Koramadai Karuppusamy Kamaleshwaran^,, Elumalai Ramkumar, Madhu Sairam Raghunathan¹

Department of Nuclear Medicine, PET/CT and Radionuclide Therapy, Coimbatore, Tamil Nadu, India

1Department of Radiotherapy, Kovai Medical Center and Hospital Limited, Coimbatore, Tamil Nadu, India

Address for correspondence: Dr. Koramadai Karuppusamy Kamaleshwaran, Department of Nuclear Medicine, PET/CT and Radionuclide Therapy, Kovai Medical Center and Hospital Limited, Coimbatore - 641 014, Tamil Nadu, India. E-mail: dr.kamaleshwar@gmail.com

Received: 2022-09-29, Accepted: 2022-12-27, Published: 2023-10

Licence

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Disclaimer:
This article was originally published by Wolters Kluwer - Medknow and was migrated to Scientific Scholar after the change of Publisher.

Abstract

Glioblastoma (GBM) is the most aggressive primary brain tumor in adults that accounts for nearly 20% of all primary malignant brain tumors. While GBM is notable for local recurrence and invasion, extracranial metastases (ECMs) are exceedingly rare, occurring in <2% of patients. However, the report of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) imaging in evaluating ECM is limited, and the importance of whole-body FDG PET/CT imaging in GBM has not been well elucidated. We present here a case of GBM, post excision 12 years before, whole-body ¹⁸F-FDG PET/CT showing no recurrence in the brain and ECM to multiple bones, right kidney, and pancreas.

Keywords

18F-fluorodeoxyglucose positron emission tomography/computed tomography

extracranial metastases

glioblastoma

whole body

Show Related Articles from PubMed

A 41-year-old man underwent right parietal lesion excision in 2010 which showed WHO grade II fibrillary astrocytoma and radiotherapy was given. He had multiple recurrences in the brain, last biopsy done in 2013 showed glioblastoma (GBM) WHO grade IV, and underwent surgery and radiotherapy. He presented with right hip pain and difficulty in walking in 2021. Magnetic resonance imaging showed a large lesion in the right femur, for which he underwent removal of the lesion and right hip prosthesis. Biopsy showed GBM metastases. He was referred for ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) to rule out extracranial metastases (ECMs) whole-body PET/CT [maximum intensity projection Figure 1a] showed intensely hypermetabolic lesions in the body of the pancreas [Figure 1b], lower pole of the right kidney [Figure 1c], and multiple bone lesions including a left humerus and multiple ribs [left iliac bone Figure 1d]. Brain PET [Figure 2] showed no recurrent brain lesion.

Whole-body MIP (a) axial fused 18F-FDG PET/CT image showing pancreatic lesion (b) right kidney lesion (c), and right iliac bone lesion (d). MIP: Maximum intensity projection, 18F-FDG PET/CT: 18F-fluorodeoxyglucose positron emission tomography/computed tomography

18F-FDG-fused PET/CT brain image showing no recurrence. 18F-FDG: 18F-fluorodeoxyglucose, PET/CT: Positron emission tomography/computed tomography

GBM is the most aggressive primary brain tumor and despite standard treatment with surgery, radiotherapy, and chemotherapy with temozolomide, the median survival time for GBM is only 15 months.[1] ECM of GBM is rare, with a reported incidence of about 0.4% to 2.0%.[2] The prognosis of metastatic GBM is poor, with median overall survival from diagnosis of metastasis of 6.0 ± 0.8 months.[3]

The rarity of ECM is attributed to the short survival period, presence of blood–brain barrier, and the lack of a classic lymphatic drainage system. In a recent meta-analysis by Cunha and Maldaun[4] of 114 cases of metastatic GBM, most cases involved metastases in a single organ or site, and to the best of our knowledge, only 12 cases of GBM multisite metastases have been described with or without intracranial recurrence. The most common metastatic sites include lungs, pleura, lymph nodes, liver, skin, scalp, parotid gland, spleen, pancreas, bowel mesentery, peritoneum, epidural space, and bones. Piccirilli et al.[5] reported that common metastatic sites included lungs and pleura (60%), lymph nodes (51%), and bones.

However, the report of ¹⁸F-FDG PET/CT imaging in evaluating ECM is limited, and the importance of whole-body ¹⁸F-FDG PET/CT imaging in ECM has not been well elucidated.[6,7] Mirzayan et al. reported the usefulness of whole-body ¹⁸F-FDG PET/CT in detecting ECM in GBM.[8] In our case, the patient developed ECM in bone after 11 years and underwent surgery and radiotherapy. ¹⁸F-FDG PET/CT showed ECM to the pancreas and kidney which is rare along with multiple skeletal metastases.

In conclusion, long-term survivors of GBM may be at increased risk of developing ECM. Rigorous follow-up should be carried out in patients with GBM with ¹⁸F-FDG PET/CT whole body and aggressive locoregional and systemic treatments are necessary to reduce recurrence and metastasis and prolong survival.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given his consent for his images and other clinical information to be reported in the journal. The patient understands that his name and initials will not be published and due efforts will be made to conceal his identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-96.
[Google Scholar]
Hamilton JD, Rapp M, Schneiderhan T, Sabel M, Hayman A, Scherer A, . Glioblastoma multiforme metastasis outside the CNS: Three case reports and possible mechanisms of escape. J Clin Oncol. 2014;32:e80-4.
[Google Scholar]
Liu J, Shen L, Tang G, Tang S, Kuang W, Li H, . Multiple extracranial metastases from glioblastoma multiforme: A case report and literature review. J Int Med Res. 2020;48:1-10.
[Google Scholar]
Cunha ML, Maldaun MV. Metastasis from glioblastoma multiforme: A meta-analysis. Rev Assoc Med Bras (1992). 2019;65:424-33.
[Google Scholar]
Piccirilli M, Brunetto GM, Rocchi G, Giangaspero F, Salvati M. Extra central nervous system metastases from cerebral glioblastoma multiforme in elderly patients. Clinico-pathological remarks on our series of seven cases and critical review of the literature. Tumori. 2008;94:40-51.
[Google Scholar]
Li ZG, Mu HY. Extracranial bone metastases from recurrent anaplastic astrocytoma on FDG PET/CT: A case report a care-compliant article. Medicine (Baltimore). 2017;96:e7123.
[Google Scholar]
Kay MD, Pariury HE, Perry A, Winegar BA, Kuo PH. Extracranial metastases from glioblastoma with primitive neuronal components on FDG PET/CT. Clin Nucl Med. 2020;45:e162-4.
[Google Scholar]
Mirzayan MJ, Samii M, Petrich T, Börner AR, Knapp WH, Samii A. Detection of multiple extracranial metastases from glioblastoma multiforme by means of whole-body [18F] FDG-PET. Eur J Nucl Med Mol Imaging. 2005;32:853.
[Google Scholar]

Declaration of patient consent
Financial support and sponsorship
Conflicts of interest

Fulltext Views
38

PDF downloads
17

View/Download PDF
Download Citations

BibTeX
RIS

Show Sections

[1] Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-96.
[Google Scholar]

[2] Hamilton JD, Rapp M, Schneiderhan T, Sabel M, Hayman A, Scherer A, . Glioblastoma multiforme metastasis outside the CNS: Three case reports and possible mechanisms of escape. J Clin Oncol. 2014;32:e80-4.
[Google Scholar]

[3] Liu J, Shen L, Tang G, Tang S, Kuang W, Li H, . Multiple extracranial metastases from glioblastoma multiforme: A case report and literature review. J Int Med Res. 2020;48:1-10.
[Google Scholar]

[4] Cunha ML, Maldaun MV. Metastasis from glioblastoma multiforme: A meta-analysis. Rev Assoc Med Bras (1992). 2019;65:424-33.
[Google Scholar]

[5] Piccirilli M, Brunetto GM, Rocchi G, Giangaspero F, Salvati M. Extra central nervous system metastases from cerebral glioblastoma multiforme in elderly patients. Clinico-pathological remarks on our series of seven cases and critical review of the literature. Tumori. 2008;94:40-51.
[Google Scholar]

[6] Li ZG, Mu HY. Extracranial bone metastases from recurrent anaplastic astrocytoma on FDG PET/CT: A case report a care-compliant article. Medicine (Baltimore). 2017;96:e7123.
[Google Scholar]

[7] Kay MD, Pariury HE, Perry A, Winegar BA, Kuo PH. Extracranial metastases from glioblastoma with primitive neuronal components on FDG PET/CT. Clin Nucl Med. 2020;45:e162-4.
[Google Scholar]

[8] Mirzayan MJ, Samii M, Petrich T, Börner AR, Knapp WH, Samii A. Detection of multiple extracranial metastases from glioblastoma multiforme by means of whole-body [18F] FDG-PET. Eur J Nucl Med Mol Imaging. 2005;32:853.
[Google Scholar]